- Home
- PACS vs PCVX Comparison
PACS vs PCVX Comparison
Compare PACS & PCVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | PACS | PCVX |
|---|---|---|
| Founded | 2013 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.8B | 6.1B |
| IPO Year | 2024 | 2020 |
Fundamental Metrics
Financial Performance| Metric | PACS | PCVX |
|---|---|---|
| Price | $41.27 | $46.10 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 7 |
| Target Price | $35.00 | ★ $105.00 |
| AVG Volume (30 Days) | 1.2M | ★ 1.3M |
| Earning Date | 03-13-2026 | 02-24-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 176.35 | N/A |
| EPS | ★ 1.04 | N/A |
| Revenue | ★ $5,138,841,000.00 | N/A |
| Revenue This Year | $32.53 | N/A |
| Revenue Next Year | $7.71 | N/A |
| P/E Ratio | $39.28 | ★ N/A |
| Revenue Growth | ★ 37.58 | N/A |
| 52 Week Low | $7.50 | $27.66 |
| 52 Week High | $40.93 | $93.77 |
Technical Indicators
Market Signals| Indicator | PACS | PCVX |
|---|---|---|
| Relative Strength Index (RSI) | 83.98 | 49.59 |
| Support Level | $37.55 | $43.95 |
| Resistance Level | $40.04 | $47.76 |
| Average True Range (ATR) | 1.56 | 1.83 |
| MACD | -0.17 | -0.11 |
| Stochastic Oscillator | 85.91 | 52.65 |
Price Performance
Historical ComparisonAbout PACS PACS Group Inc.
PACS Group Inc is a post-acute healthcare company mainly focused on delivering high-quality skilled nursing care through a portfolio of independently operated facilities Its is a nursing providers in the United States based on number of facilities, with over 200 post-acute care facilities across nine states serving over 20,000 patients daily. It also provide senior care, assisted living, and independent living options in some of communities.
About PCVX Vaxcyte Inc.
Vaxcyte Inc is a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases. It is developing broad-spectrum conjugate and novel protein vaccines to prevent or treat bacterial infectious diseases. Its product comprises of Pneumococcal conjugate vaccine. The firm's product candidate consists of VAX-31, VAX-24, VAX-A1, VAX-PG, VAX-GI, and Others.